The Role of Theranostics in Prostate Cancer.

ABSTRACT: Theranostics in men with metastatic castration-resistant prostate cancer (mCRPC) has been developed to target bone and the tumor itself. Currently, bone-directed targeted alpha therapy with radium-223 (²²³Ra) is the only theranostic agent proven to prolong survival in men with mCRPC who have symptomatic bone metastases and no known visceral metastases. The clinical utility and therapeutic success of ²²³Ra has encouraged the development of other tumor-targeting theranostic agents in mCRPC, primarily targeting prostate-specific membrane antigen (PSMA) with radioligand therapy (RLT). There is increasing evidence of promising response rates and a low toxicity profile with ¹⁷⁷Lu-labeled PSMA RLT in patients with mCRPC. A phase III randomized study of ¹⁷⁷

SUBMITTER: O'Dwyer E 

PROVIDER: S-EPMC8391014 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature